iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

iCAD, Inc.

iCAD develops artificial intelligence solutions for cancer detection, specifically focusing on breast cancer screening and assessment. The company provides AI-powered tools for detection, density assessment, and risk evaluation.

msh id	COM:ICADMED
symbol	ICAD
name	iCAD, Inc.
homepage url	https://www.icadmed.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	67
crunchbase url	-
linkedin url	-
founders	-

market cap	34.5M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.4
growth cost of revenue	-0.66
growth depreciation and amortization	-0.41
growth ebitda	0.45
growth ebitda ratio	0.11
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.17
growth gross profit	-0.27
growth gross profit ratio	0.18

COM:ICADMED

iCAD

Last Close

1.54

21/11 21:00

Market Cap

34.50M

Beta: -

Volume Today

221.98K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	25.01M
cost of revenue	25.01M
depreciation and amortization	409K
ebitda	-7.28M
ebitda ratio	-0.42
eps	-0.19
eps diluted	-0.19
operating expenses	22.23M
operating income	-7.69M
operating income ratio	-0.44

accounts receivables	-1.75M
capital expenditure	-1.28M
cash at beginning of period	21.31M
cash at end of period	21.67M
inventory	917K
working capital ttm	20.93M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-